Compare Incyte Corporation (INCY) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sirius XM Holdings Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Sirius XM Holdings Inc trades at $28.42 (market cap $9.70B). The key difference: Incyte Corporation is far larger — about 2.5× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SIRI | |
|---|---|---|
Market Cap | $24.54B | $9.70B |
Sector | Health | Media |
52-Week High | $129.93 | $32.59 |
52-Week Low | $81.61 | $19.92 |
Enterprise Value | $20.04B | $18.98B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Sirius XM Holdings (SIRI) trades at $28.40, down 1.32% with bearish technical signals despite attractive valuation metrics including P/E of 11.56 and P/B of 0.81. The company reported mixed Q2 2026 results with a revenue beat but earnings miss, while maintaining stable cash flow and announcing a $0.27 dividend. Recent news highlights satellite communications growth potential and institutional positioning.
SIRI presents a value opportunity with strong cash generation and dividend yield, though near-term headwinds include subscriber challenges and debt levels. Analyst consensus remains bullish with $33.17 price target representing 17% upside, but investors should monitor execution on subscriber retention and competitive pressures in the evolving audio streaming landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
